© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Merck’s experimental HIV drug proves effective and well tolerated
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.
Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.
Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.
Merck’s investigational antiretroviral could one day be dosed only weekly among humans.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
